U.S.S.N. 10/099,830 Filed: March 13, 2002

## AMENDMENT AND RESPONSE TO OFFICE ACTION

## In the Claims

Claims 1-33 (Canceled).

34. (currently amended) A therapeutic system comprising a prodrug which is converted to a substantially cytotoxic drug by the action of NQO2 and a compound of formula I

wherein R1 is selected from the group consisting of substituted alkyl, including substitution by CONH<sub>2</sub>, OH, halogen, CN, and COOH; aryl; substituted aryl; CONR<sub>a</sub>R<sub>b</sub>, where R<sub>a</sub> and R<sub>b</sub> are independently H, alkyl, or substituted alkyl, and R<sup>2</sup> and R<sup>3</sup> are independently H, alkyl, or substituted alkyl, halogen, CN, COOH, alkyl, or substituted alkyl and R<sup>4</sup> is any of H, alkyl, substituted alkyl, halogen, CN, COOH, CONH<sub>2</sub>, or OH, wherein the compound can pass reducing equivalents to NQO2, in a form for administration to a patient in need thereof, wherein the prodrug is CB 1954.

Claims 35-40 (Canceled)

41. (Previously Presented) The system of claim 34, wherein the compound is 1-(carboxamidomethyl)-dihydronicotinamide.

45054721

2

ERD 100 CON 078230/00031 U.S.S.N. 10/099,830
Filed: March 13, 2002
AMENDMENT AND RESPONSE TO OFFICE ACTION

42. (previously presented) The system of claim 34, wherein the compound has formula

wherein R is a substituted alkyl, comprising one or more groups selected from the group consisting of CONH<sub>2</sub>, OH, halogen, CN, and COOH.

- 43. (Previously Presented) The system of claim 34, wherein the alkyl group is a C1 to C6 alkyl.

45-47. (Canceled)

45054721

 $\mathbf{II}$ 

3

ERD 100 CON 078230/00031